MAY 17, 2018 05:00 AM PDT

Accelerating Bio-Production Using ExpiCHO Stable Production Medium

  • Scientist II, Cell Biology, Thermo Fisher Scientific
      Shreya received her Masters of Science degree in Pharmaceutical Sciences from the School of Pharmacy and Pharmaceutical Sciences at the University at Buffalo. Her research focused on disease progression in multiple sclerosis patients with a particular emphasis in lipid and cholesterol derivative analysis. She has previous experience as a Research Technician at the University at Buffalo, Department of Microbiology and Immunology where she gained a vast knowledge in molecular biology techniques. She joined as a Scientist in Gibco Bioproduction Services in 2016 with her current research efforts focusing on mammalian cell culture optimization, New Product Introduction, cell line and process development.


    Many research laboratories use the ExpiCHO Expression System to transiently produce candidate biomolecules for biologics development. However, after the lead candidate is found, a stable cell clone expressing the protein of interest is in many instances desired. Thermo Fisher Scientific has recently developed tools to help researchers that are interested in generating ExpiCHO-S-derived stable clones capable of producing high titers and scaling up into a large bio-production process. The high costs and time involved to create and adapt stable cell lines into a suitable production medium can be laborious. ExpiCHO Stable Production Medium provides a seamless transition from transient expression to ExpiCHO stable production, requiring minimal to no cell adaptation. We have generated ExpiCHO-S stable cell lines that produce up to 3.5 more protein than stable clones from traditional CHO-S cells. With our new ExpiCHO Stable Production Medium, Thermo Fisher Scientific provides a clear path toward creating higher-producing stable ExpiCHO-S cell lines while supporting the scalability and product quality attributes important for cell line development.

    Show Resources
    Loading Comments...